Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3200327 in Healthy Subjects
NCT02595736Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2015
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3200327 in systemic lupus erythematosus (SLE) and Sjögren's syndrome (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) at 12 weeks. Started Nov 2015; status: completed.
02
Drugs
LY3200327
03
Conditions
systemic lupus erythematosus (SLE)Sjögren's syndrome
Beyond the preview
Go deeper on NCT02595736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595736.